Characteristics and laboratory findings on admission of 6 patients with iTTP used in microfluidic assays
| Parameter . | Reference‡ . | iTTP (n = 6) . |
|---|---|---|
| Age (years) | — | 53.8 ± 13.8∗ |
| Gender, male, n (%) | — | 3 (50.0) |
| Comorbidities | ||
| Hypertension, n (%) | — | 2 (33.3) |
| Diabetes, n (%) | — | 0 (0) |
| Chronic kidney disease, n (%) | — | 2 (33.3) |
| History of malignancy, n (%) | — | 2 (33.3) |
| White Blood Cell (× 109/L) | 4.5-11.0 | 10.7 ± 3.0∗ |
| Neutrophil (× 109/L) | 4.1-7.7 | 8.5 ± 2.3∗ |
| Hemoglobin (g/dL) | 12.0-16.5 | 9.4 ± 3.9∗ |
| Hematocrit (%) | 36-50 | 27.0 ± 11.6∗ |
| Platelet count (× 109/L) | 150-400 | 9.7 ± 4.8∗ |
| ADAMTS13 activity (IU/dL) | 40-133 | |
| Anti-ADAMTS13 IgG (U/mL) | <15 | 0 (0-0.7)† |
| Positive | ||
| LDH (IU/L) | 100-200 | 1444 ± 836∗ |
| Creatinine (mg/dL) | 0.46-1.09 | 1.7 ± 1.1∗ |
| INR | 0.85-1.15 | 1.2 ± 0.2∗ |
| APTT (sec) | 20-40 | 29.0 ± 2.1∗ |
| Parameter . | Reference‡ . | iTTP (n = 6) . |
|---|---|---|
| Age (years) | — | 53.8 ± 13.8∗ |
| Gender, male, n (%) | — | 3 (50.0) |
| Comorbidities | ||
| Hypertension, n (%) | — | 2 (33.3) |
| Diabetes, n (%) | — | 0 (0) |
| Chronic kidney disease, n (%) | — | 2 (33.3) |
| History of malignancy, n (%) | — | 2 (33.3) |
| White Blood Cell (× 109/L) | 4.5-11.0 | 10.7 ± 3.0∗ |
| Neutrophil (× 109/L) | 4.1-7.7 | 8.5 ± 2.3∗ |
| Hemoglobin (g/dL) | 12.0-16.5 | 9.4 ± 3.9∗ |
| Hematocrit (%) | 36-50 | 27.0 ± 11.6∗ |
| Platelet count (× 109/L) | 150-400 | 9.7 ± 4.8∗ |
| ADAMTS13 activity (IU/dL) | 40-133 | |
| Anti-ADAMTS13 IgG (U/mL) | <15 | 0 (0-0.7)† |
| Positive | ||
| LDH (IU/L) | 100-200 | 1444 ± 836∗ |
| Creatinine (mg/dL) | 0.46-1.09 | 1.7 ± 1.1∗ |
| INR | 0.85-1.15 | 1.2 ± 0.2∗ |
| APTT (sec) | 20-40 | 29.0 ± 2.1∗ |